This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Multiple Myeloma
and you are
over 18
years old
Phase
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.

Provided treatments

  • Procedure: Autologous peripheral blood stem cell transplant
  • Drug: Lenalidomide
  • Drug: Dexamethasone
  • Procedure: Stem cell collection
Tris trial is registered with FDA with number: NCT01731886. The sponsor of the trial is Columbia University and it is looking for 12 volunteers for the current phase.
Official trial title:
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma